Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01648257 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study of GSK1265744 Formulations
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01648257 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 18 participants.
The verdict
NCT01648257, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a single-center, randomized, open-label, balanced, 3 way crossover study (3 periods) in healthy adult subjects. During each period, subjects will receive a single dose of GSK1265744 oral formulation in the fasted state and serial PK sampling for up to 168 hours (8 days) and safety assessments will be performed. Each period will be separated by a washout period of at least 14 days and a follow-up visit will occur 10 to 14 days after the last dose of study drug.
Interventions
- DRUG GSK1265744 Na Salt Tablets
- DRUG GSK1265744 Free Acid Nanomilled Capsules
- DRUG GSK1265744 Free Acid Micronized Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-08 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01648257
The ClinicalTrials.gov registry entry for NCT01648257 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GSK1265744 Na Salt Tablets is the first listed.
NCT01648257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01648257 about?
NCT01648257 is a clinical study titled "Relative Bioavailability Study of GSK1265744 Formulations". This is a single-center, randomized, open-label, balanced, 3 way crossover study (3 periods) in healthy adult subjects. During each period, subjects will receive a single dose of GSK1265744 oral formulation in the fasted state and serial PK sampling for up to 168 hours (8 days) and safety assessment...
What is the current status of trial NCT01648257?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2012-08. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01648257?
The interventions under investigation include: GSK1265744 Na Salt Tablets (DRUG), GSK1265744 Free Acid Nanomilled Capsules (DRUG), GSK1265744 Free Acid Micronized Capsules (DRUG).
Who is sponsoring clinical trial NCT01648257?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.